The Lancet JANUARY 02, 1999

The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial

The CIBIS-II Investigators and Committees

Bottom Line

The CIBIS-II trial demonstrated that the addition of the beta-1 selective blocker bisoprolol to standard therapy significantly reduced all-cause mortality in patients with chronic heart failure.

Key Findings

1. Bisoprolol significantly reduced all-cause mortality compared to placebo, with an event rate of 11.8% in the bisoprolol group versus 17.3% in the placebo group (Hazard Ratio [HR] 0.66; 95% CI 0.54-0.81; p < 0.0001).

2. There was a 44% relative reduction in the risk of sudden cardiac death, with rates of 3.6% in the bisoprolol group compared to 6.3% in the placebo group (HR 0.56; 95% CI 0.39-0.80; p = 0.0011).

3. The trial was terminated early after a planned interim analysis confirmed the significant mortality benefit.

4. Treatment effects were observed consistently across different subgroups, regardless of the severity or underlying etiology of the heart failure.

Study Design

Design

RCT

Double-Blind

Sample

2,647

Patients

Duration

1.3 yr

Median

Setting

Multicenter, Europe

Population Symptomatic patients with NYHA class III or IV heart failure and left-ventricular ejection fraction of 35% or less, currently receiving stable standard therapy with diuretics and ACE inhibitors.

Intervention Bisoprolol initiated at 1.25 mg daily, titrated upward as tolerated to a target maximum of 10 mg daily.

Comparator Placebo administered in addition to standard therapy.

Outcome All-cause mortality.

Study Limitations

• The trial was stopped early, which may have led to an overestimation of the treatment effect size.

• The results are not directly generalizable to patients with very severe NYHA class IV symptoms who are hemodynamically unstable, as they were underrepresented or excluded.

• The study design required titration, and patients who could not tolerate the drug in the initial phase might not have been fully captured in the long-term effectiveness data.

Clinical Significance

CIBIS-II was a landmark study that reversed the long-standing clinical dogma that beta-blockers were contraindicated in heart failure, ultimately establishing beta-blockade as a foundational component of guideline-directed medical therapy (GDMT) for HFrEF.

Historical Context

Prior to the late 1990s, beta-blockers were generally avoided in patients with heart failure due to concerns regarding their negative inotropic effects. CIBIS-II followed the earlier CIBIS-I trial, which suggested a trend toward benefit, and provided the definitive evidence needed to shift clinical practice globally.

Guided Discussion

High-yield insights from every perspective

Med Student

Medical Student

Why was the introduction of beta-blockers like bisoprolol initially considered counterintuitive in heart failure management, and what is the pathophysiology of the 'sympathetic overdrive' they aim to mitigate?

Key Response

Historically, beta-blockers were contraindicated in heart failure because of their negative inotropic effects. However, CIBIS-II helped prove that the chronic activation of the sympathetic nervous system leads to maladaptive remodeling, increased oxygen demand, and arrhythmia. Blocking this pathway with bisoprolol allows for reverse remodeling and long-term improvement in ejection fraction despite a transient initial decrease in contractility.

Resident

The CIBIS-II trial utilized a specific 'start low, go slow' titration protocol. What are the key clinical monitoring parameters during the titration phase, and how would you manage a patient who develops asymptomatic bradycardia during this process?

Key Response

The trial started bisoprolol at 1.25 mg with slow upward titration. Residents must monitor for hypotension, bradycardia, and worsening fluid retention. Asymptomatic bradycardia (e.g., HR 50-60 bpm) usually does not require dose reduction, as the mortality benefit is dose-dependent. Management involves ensuring the patient remains stable and only intervening if symptomatic heart block or significant hemodynamic compromise occurs.

Fellow

How do the results of CIBIS-II, which focused on a beta-1 selective agent, compare to the COMET trial results regarding the choice of beta-blocker in HFrEF, and what are the implications for patients with concomitant reactive airway disease?

Key Response

CIBIS-II established bisoprolol's efficacy, while COMET suggested carvedilol (non-selective) might be superior to metoprolol tartrate. For fellows, the nuance lies in balancing the carvedilol data with the beta-1 selectivity of bisoprolol, which is often preferred in patients with COPD or mild asthma to avoid bronchospasm while still providing the mortality benefits demonstrated in CIBIS-II.

Attending

CIBIS-II was terminated early after the second interim analysis due to highly significant mortality benefits. As a clinician, how does early termination affect your interpretation of the treatment effect size and the 'number needed to treat' (NNT)?

Key Response

Trials stopped early for benefit can sometimes exaggerate the treatment effect (overestimation of the Hazard Ratio). However, with an NNT of 19 for mortality over 1.3 years, the benefit was so robust that it transformed the standard of care. Attendings must teach that while the effect might be slightly less in real-world heterogeneous populations, the mandate for therapy remains absolute.

Scholarly Review

Critical appraisal through the lens of expert reviewers and guideline development

PhD

Critique the use of the O'Brien-Fleming stopping boundaries in the CIBIS-II trial design. How does this statistical approach maintain the integrity of the alpha level across multiple interim analyses compared to a fixed-sample design?

Key Response

O'Brien-Fleming boundaries are conservative early in the trial, requiring a very small p-value to stop early, which preserves the overall Type I error rate (0.05). This approach addresses the 'multiplicity' problem of looking at the data multiple times, ensuring that the trial only stops if the evidence is overwhelming, as it was in CIBIS-II (p < 0.0001).

Journal Editor

In CIBIS-II, the heart rate reduction in the treatment group could potentially lead to 'functional unblinding.' To what extent does this threat to internal validity undermine the reported improvements in NYHA functional class vs. all-cause mortality?

Key Response

Editors look for 'unblinding' where side effects (bradycardia) allow investigators to guess the treatment arm. While NYHA class (subjective) could be influenced by this bias, all-cause mortality (the primary endpoint) is an objective 'hard' endpoint that remains robust regardless of unblinding, which is why the trial's conclusions remain high-impact.

Guideline Committee

Based on CIBIS-II and subsequent meta-analyses, bisoprolol is a Class I, Level A recommendation in HF guidelines. How should the committee address the 'ceiling effect' of beta-blocker dosing when patients achieve the target heart rate but not the target trial dose?

Key Response

Guidelines (ACC/AHA/ESC) emphasize reaching the target doses used in trials like CIBIS-II (10mg daily). However, clinical reality often involves dose-limiting bradycardia. The committee must decide if 'maximal tolerated dose' or 'target heart rate' should be the priority, though CIBIS-II evidence is strictly based on dose titration attempts, not heart rate targets.

Clinical Landscape

Noteworthy Related Trials

1996

US Carvedilol Heart Failure Study

n = 1,094 · NEJM

Tested

Carvedilol

Population

Patients with symptomatic heart failure and ejection fraction <35%

Comparator

Placebo

Endpoint

All-cause mortality

Key result: Carvedilol treatment was associated with a 65% reduction in the risk of death compared to placebo.

1999

MERIT-HF

n = 3,991 · Lancet

Tested

Metoprolol succinate

Population

Chronic heart failure patients with NYHA class II-IV

Comparator

Placebo

Endpoint

All-cause mortality

Key result: Treatment with metoprolol succinate reduced all-cause mortality by 34% compared to placebo.

2002

COPERNICUS

n = 2,289 · NEJM

Tested

Carvedilol

Population

Patients with severe chronic heart failure

Comparator

Placebo

Endpoint

All-cause mortality

Key result: Carvedilol significantly reduced the risk of death by 35% in patients with severe heart failure.

Tailored to your role

Want this tailored to you?

Add your specialty or training stage to get role-specific takeaways and more questions.

Personalize this analysis